Journal article
Population Pharmacokinetics of Perphenazine in Schizophrenia Patients from CATIE: Impact of Race and Smoking
Journal of clinical pharmacology, Vol.50(1), pp.73-80
01/2010
DOI: 10.1177/0091270009343694
PMCID: PMC3648660
PMID: 19843655
Abstract
The goal of the study was to characterize population pharmacokinetics (PPK) for perphenazine in patients with schizophrenia from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Patients (n = 156) received 8–32 mg of perphenazine daily for 14 to 600 days for a total of 421 plasma concentrations measurements. Nonlinear mixed-effects modeling was used to determine PPK characteristics of perphenazine. One-and two-compartment models with various random effect implementations and mixture distributions were evaluated. Objective function values and goodness of fit plots were used as model selection criteria. Age, weight, sex, race, smoking, and concomitant medications were evaluated as covariates. A one-compartmental linear model with proportional error best described the data. The population mean clearance and volume of distribution for perphenazine were 483 L/h and 18,200 L, respectively. Race and smoking status had significant impacts on perphenazine clearance estimates. In addition, the estimated population mean clearance was 48% higher in nonsmoking African Americans than in nonsmoking other races (512 L/h versus 346 L/h). Active smokers eliminated perphenazine 159 L/h faster than nonsmokers in each race. Clearances for smoking African Americans versus smokers in other races were 671 L/h versus 505 L/h, respectively.
Details
- Title: Subtitle
- Population Pharmacokinetics of Perphenazine in Schizophrenia Patients from CATIE: Impact of Race and Smoking
- Creators
- Yuyan Jin - Columbia University Medical Center, Department of Psychiatry, New York City, NYBruce G Pollock - Columbia University Medical Center, Department of Psychiatry, New York City, NYKim Coley - Columbia University Medical Center, Department of Psychiatry, New York City, NYDel Miller - Columbia University Medical Center, Department of Psychiatry, New York City, NYStephen R Marder - Columbia University Medical Center, Department of Psychiatry, New York City, NYJeff Florian - Columbia University Medical Center, Department of Psychiatry, New York City, NYLon Schneider - Columbia University Medical Center, Department of Psychiatry, New York City, NYJeff Lieberman - Columbia University Medical Center, Department of Psychiatry, New York City, NYMargaret Kirshner - Columbia University Medical Center, Department of Psychiatry, New York City, NYRobert R Bies - Columbia University Medical Center, Department of Psychiatry, New York City, NY
- Resource Type
- Journal article
- Publication Details
- Journal of clinical pharmacology, Vol.50(1), pp.73-80
- DOI
- 10.1177/0091270009343694
- PMID
- 19843655
- PMCID
- PMC3648660
- NLM abbreviation
- J Clin Pharmacol
- ISSN
- 0091-2700
- eISSN
- 1552-4604
- Grant note
- P30 MH052247-05 || MH / National Institute of Mental Health : NIMH K24 MH065416-01 || MH / National Institute of Mental Health : NIMH P50 AG005142-26A16897 || AG / National Institute on Aging : NIA
- Language
- English
- Date published
- 01/2010
- Academic Unit
- Psychiatry
- Record Identifier
- 9984004090202771
Metrics
37 Record Views